for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Diffusion Pharmaceuticals Inc

DFFN.OQ

Latest Trade

0.91USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.22

 - 

2.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Diffusion Pharma Names Director Dr. Robert Cobuzzi As President And CEO

Sept 8 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS NAMES DIRECTOR DR. ROBERT COBUZZI AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.DIFFUSION PHARMACEUTICALS - ROBERT COBUZZI JR., WILL SUCCEED DAVID G. KALERGIS AS PRESIDENT AND CHIEF EXECUTIVE OFFICER EFFECTIVE IMMEDIATELY.DIFFUSION PHARMACEUTICALS - KALERGIS WILL RETIRE FROM HIS OPERATIONAL RESPONSIBILITIES BUT CONTINUE TO SERVE AS CHAIRMAN OF BOARD.

Diffusion Pharmaceuticals Reports Qtrly Loss Per Share $0.10

Aug 10 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.DIFFUSION PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.10.DIFFUSION PHARMACEUTICALS- BELIEVES CASH, EQUIVALENTS AS OF JUNE 30 SUFFICIENT TO FUND EXPENSES, CAPEX INTO Q4 OF 2021.DIFFUSION PHARMACEUTICALS - HAD CASH, EQUIVALENTS OF $25.6 MILLION AS OF JUNE 30.

Diffusion - Entire Phase 1A/1B Trial Will Enroll About 224 Patients And Is Expected To Last Approximately 12 Months

Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS FILES CLINICAL TRIAL APPLICATION FOR EUROPEAN PHASE 1A/1B STUDY OF TSC IN COVID-19 PATIENTS.DIFFUSION - SUBMISSION OF CTA TO ROMANIAN NATIONAL AGENCY FOR MEDICINES & MEDICAL DEVICES FOR EUROPEAN PHASE 1A/1B STUDY OF TSC IN COVID-19 PATIENTS.DIFFUSION - ENTIRE PHASE 1A/1B TRIAL WILL ENROLL ABOUT 224 PATIENTS AND IS EXPECTED TO LAST APPROXIMATELY 12 MONTHS.

Diffusion Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement

June 1 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT.

Diffusion Pharma Files Prospectus Related To Resale Of Shares By Selling Stockholders

May 29 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATES TO RESALE, FROM TIME TO TIME, BY SELLING STOCKHOLDERS OF UP TO 5.8 MILLION SHARES OF COMMON STOCK.

Diffusion Pharmaceuticals Announces Pre-Ind Submission To The FDA Of Design For Tsc Trials To Treat Acute Respiratory Distress Syndrome In Covid-19

Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS ANNOUNCES PRE-IND SUBMISSION TO THE FDA OF DESIGN FOR TSC TRIALS TO TREAT ACUTE RESPIRATORY DISTRESS SYNDROME IN COVID-19.DIFFUSION PHARMACEUTICALS INC - PATIENT ENROLLMENT PLANNED FOR BOTH U.S. AND EASTERN EUROPE.

Diffusion Pharmaceuticals Reports 2019 Financial Results And Provides Business Update

March 17 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS REPORTS 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.DIFFUSION PHARMACEUTICALS - ANTICIPATE ENROLLMENT IN PHAST-TSC WILL CONTINUE DURING YEAR, WITH EXPECTATION OF COMPLETING STUDY BEFORE MID-2021.DIFFUSION PHARMACEUTICALS INC - BELIEVES HAS ADEQUATE CASH RESOURCES TO CONTINUE OPERATIONS INTO JANUARY OF 2021.

Diffusion Pharmaceuticals Files For Offering Of 6.6 Million Shares

Dec 20 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS FILES FOR OFFERING OF 6.6 MILLION SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF OUTSTANDING WARRANTS BY SELLING STOCKHOLDERS.

Diffusion Pharmaceuticals Announces $3.Mln Million Registered Direct Offering Priced At-The-Market

Dec 12 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS INC. ANNOUNCES $3.5 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.DIFFUSION PHARMACEUTICALS INC - ENTERED INTO DEFINITIVE SECURITIES PURCHASE AGREEMENTS WITH CERTAIN INSTITUTIONAL INVESTORS.DIFFUSION - TO PURCHASE IN REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET 6.3 MILLION SHARES OF CO'S COMMON STOCK, AT PURCHASE PRICE OF $0.4335/SHARE.

Diffusion Pharmaceuticals Says Received Delisting Notice From Nasdaq

Dec 11 (Reuters) - Diffusion Pharmaceuticals Inc <DFFN.O>::DIFFUSION PHARMACEUTICALS - ON DEC 11, CO RECEIVED A WRITTEN NOTICE OF DELISTING FROM NASDAQ - SEC FILING.DIFFUSION PHARMACEUTICALS - STAFF OF LISTING QUALIFICATIONS DEPARTMENT OF NASDAQ ADVISED CO THAT IT INTENDS TO ISSUE PUBLIC REPRIMAND LETTER TO CO.DIFFUSION PHARMACEUTICALS - PUBLIC REPRIMAND LETTER IN CONNECTION WITH CO'S PUBLIC OFFERING PURSUANT TO REGISTRATION STATEMENT ON FORM S-1.DIFFUSION PHARMACEUTICALS - REPRIMAND LETTER IN CONNECTION WITH OFFERING BASED ON STAFF'S BELIEF THAT OFFERING DID NOT MEET "PUBLIC OFFERING" CRITERIA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up